natgillin/translations-raw huggingface dataset:
Glutamyltransferase10 High Uric Acid 10
glutamiltransferaza10 visoka razina mokraćne kiseline10
Gluteal
glutealni mišić
Glybera contains the human LPL gene variant LPL S447X in an adeno-associated virus serotype 1 (AAV1) vector intended to target the muscle.
Glybera sadrži humani gen za lipoproteinsku lipazu varijanta LPL S447X u vektoru od adeno-asociranog virusnog serotipa 1 (AAV1) koji je usmjeren na mišić.
Glybera has been authorised under ‘exceptional circumstances’ as it has not been possible to obtain complete information about the medicine, because of the rarity of the disease.
Lijek Glybera odobren je pod „iznimnim okolnostima” budući da nije bilo moguće dobiti potpune informacije o lijeku uslijed rijetke prirode bolesti.
Glybera is a clear to slightly opalescent, colourless solution for injection, supplied in a clear glass vial with a siliconised injection stopper and flip-off seal.
Glybera je bistra do blago opalescentna, bezbojna otopina za injekciju, koja dolazi u prozirnoj, staklenoj bočici sa silikoniziranim injekcijskim čepom i odvojivim zatvaračem.
Glybera is a gene therapy product.
Glybera je produkt genske terapije.
Glybera is a type of advanced therapy medicine called a ‘gene therapy product’.
Glybera je vrsta lijeka za naprednu terapiju koji se naziva „lijek za gensku terapiju”.
Glybera is delivered in a patient-specific pack and will therefore contain the precise amount of vials per patient, calculated according to the patient’s weight.
Glybera se dostavlja u pakiranju specifičnom za bolesnika, što znači da sadrži točan broj bočica za jednog bolesnika, koji se izračuna na temelju njegove tjelesne težine.
Glybera is delivered in a patient-specific pack and will therefore contain the precise amount of vials per patient, calculated according to the patient’s weight.
Glybera se dostavlja u pakiranju specifičnom za bolesnika, što znači da sadrži točnu količinu bočica za jednog bolesnika, koja se izračuna na temelju njegove tjelesne težine.
Glybera is injected directly into the target organ, skeletal muscle.
Glybera se injicira neposredno u ciljni organ, skeletni mišić.
Glybera should not be administered to pregnant women unless the possible benefit to the mother outweighs the possible risk to the foetus.
Glybera se ne smije primjenjivati u trudnica, osim ako su moguće koristi za majku veće od potencijalnog rizika za plod.
Glybera should not be administered to women who are breast-feeding as long as breastfeeding is ongoing.
Glybera se ne smije davati ženama koje doje, sve dok dojenje traje.
Glybera therapy must be prescribed by and administered under the supervision of a physician with expertise in treating LPLD patients and in gene therapy administration, in full consultation with the patient.
Terapija Glyberom mora biti propisana i primjenjivana pod nadzorom liječnika koji ima iskustva u liječenju bolesnika s LPLD-om i u primjeni genske terapije, pri čemu se mora o svemu posavjetovati s bolesnikom.
glyburide)
Lijek
Glycaemic control Monotherapy
Regulacija glikemije Monoterapija
Glycerol 85%
glicerol 85
Glycerol formal Disodium edetate (E385) Propyl gallate (E310) Thiodipropionic acid Dimethyl isosorbide
Glicerol formal Dinatrijev edetat (E385) Propil galat (E310) Tiodipropionska kiselina Dimetil izosorbid
Glycerol Metacresol Phenol
Glicerol Metakrezol Fenol
Glycerol Phenol Metacresol Zinc acetate
Glicerol Fenol Metakrezol Cinkov acetat
Glycerol Phenol Metacresol Zinc chloride
Glicerol Fenol Metakrezol Cinkov klorid
Glycerol phenylbutyrate given at the maximum recommended dose contains less than 0.5 g of glycerol per dose.
Glicerolfenilbutirat primijenjen u najvišoj preporučenoj dozi sadrži manje od 0,5 g glicerola po dozi.
Glycerol Sorbitol
Sorbitol
Glycerol Titanium dioxide Propylene glycol Sodium hydroxide Purified water
glicerol titanijev dioksid propilenglikol natrijev hidroksid pročišćena voda
Glycerol, metacresol, phenol, zinc acetate, hydrochloric acid and sodium hydroxide (for pH adjustment) and water for injections
glicerol, metakrezol, fenol, cinkov acetat, kloridnu kiselinu i natrijev hidroksid (za podešavanje pH) i vodu za injekcije.
glycerol, phenol, metacresol, zinc acetate, disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections
glicerol, fenol, metakrezol, cinkov acetat, natrijev hidrogenfosfat dihidrat, natrijev klorid, kloridnu kiselinu/natrijev hidroksid za podešavanje pH i vodu za injekcije.
glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections
glicerol, fenol, metakrezol, cinkov klorid, natrijev hidrogenfosfat dihidrat, natrijev klorid, kloridnu kiselinu/natrijev hidroksid za podešavanje pH i vodu za injekcije.
glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections.
glicerol, fenol, metakrezol, cinkov klorid, natrijev hidrogenfosfat dihidrat, natrijev klorid, kloridnu kiselinu/natrijev hidroksid za podešavanje pH i vodu za injekcije.
glycerol, phenol, metacresol, zinc chloride, disodium phosphate dihydrate, sodium chloride, protamine sulfate, hydrochloric acid/sodium hydroxide for pH adjustment and water for injections
glicerol, fenol, metakrezol, cinkov klorid, natrijev hidrogenfosfat dihidrat, natrijev klorid, protaminsulfat, kloridnu kiselinu/natrijev hidroksid za podešavanje pH i vodu za injekcije.
glycine disodium hydrogen phosphate heptahydrate sodium dihydrogen phosphate dihydrate
glicin dinatrijev hidrogenfosfat heptahidrat natrijev dihidrogenfosfat dihidrat
glycine disodium hydrogen phosphate heptyhydrate sodium dihydrogen phosphate dihydrate
glicin dinatrijev hidrogenfosfat heptahidrat natrijev dihidrogenfosfat dihidrat
Glycine, sodium chloride, calcium chloride, histidine, polysorbate 80, sucrose.
Glicin, natrijev klorid, kalcijev klorid, histidin, polisorbat 80, saharoza.
Glycine, water for injections.
Glicin, voda za injekcije.
Glycohaemoglobin and glucose variabilities were comparable in both treatment groups.
Varijabilnosti u vrijednostima glikiranog hemoglobina i glukoze bile su usporedive u obje terapijske skupine.
Glycopyrronium
Glikopironij
Glycopyrronium should be discontinued if pneumonia is present.
U slučaju upale pluća valja obustaviti primjenu glikopironija.
Glycopyrronium:
Glikopironij:
glycosuria
glikouzrija
glycosuria
glikozurija
Glycosuria, proteinuria
glukozurija, proteinurija
Glycosylated haemoglobin increased
Povišenje glikoziliranog hemoglobina
Glycosylated haemoglobin increased, alanine aminotransferase increased, blood glucose increased, blood creatinine phosphokinase increased
Povišenje glikoziliranog hemoglobina, povišenje alanin aminotransferaze, povišenje glukoze u krvi, povišenje kreatinin fosfokinaze u krvi
Glycosylated haemoglobin levels are also of value in monitoring the patient’s response to therapy.
Razina glikoziliranog hemoglobina je također bitna u praćenju odgovora bolesnika na liječenje.
Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics.
Glicilciklinska skupina antibiotika strukturno je slična tetraciklinskoj skupini antibiotika.
GM-CSF for remainder of IL-2 courses.
zamijeniti ga s GM-CSF-om za preostale cikluse s IL-2.
GM-CSF is given as either an injection under the skin or as a drip into one of your veins each day for 14 days.
GM-CSF se primjenjuje potkožnom injekcijom ili infuzijom kap po kap u jednu od Vaših vena svakodnevno tijekom 14 dana.
GM-CSF, n = 86)
GM-CSF, n = 55)
gMean (gCV%; range) half-life
Geometrijska srednja vrijednost (gCV%; raspon) poluvijeka
GMT (95% CI)
951,8 (705,0; 1284,9)
GMT (95%CI)
GMT (95 % CI)
GMT (95%CI)
GMT (95 %CI)
GMT (95%CI)
GMT (95% CI)
GMT=Geometric Mean Titers.
GMT=geometrijski srednji titar.
GMT=Geometric Mean Titers. cLIA= Competitive Luminex Immunoassay.
GMT=geometrijski srednji titar. cLIA=kompetitivni Luminex imunološki test.
GMTs for HPV-6, -11, -16 and -18 were numerically comparable in subjects who received qHPV vaccine or Gardasil 9 for at least 3.5 years.
GTM-ovi za tipove 6, 11, 16 i 18 HPV-a bili su brojčano usporedivi u ispitanika koji su primili cjepivo qHPV ili Gardasil 9 tijekom najmanje 3,5 godina.
GMTs were higher in girls and boys than in 16- through 26-year-old women, and higher in boys than in girls and women.
GMT-ovi su bili viši u djevojčica i dječaka nego u žena u dobi od 16 do 26 godina i viši u dječaka nego u djevojčica i žena.
GnRF analogue-protein conjugate min.
Konjugat analog-proteina gonadoliberina min.
GnRF analogue-protein conjugate: Zoetis Belgium SA
Konjugat analog-proteina gonadoliberina: Zoetis Belgium SA
go for regular breast screening and cervical smear tests, as recommended by your doctor. regularly check your breasts for any changes such as dimpling of the skin, changes in the nipple, or any lumps you can see or feel.
odlazite na redovite preglede dojki i briseve sluznice grlića maternice, prema preporukama liječnika redovito pregledavate dojke kako biste uočili sve promjene kao što su jamice na koži, promjene na bradavicama ili kvržice koje možete vidjeti ili napipati.
Go to Section 3, Step 3, for instructions on how to inject your first routine dose.
Prijeđite na Dio 3, Korak 3, za upute o tome kako injicirati prvu redovnu dozu.
Go to the hospital if you have symptoms of lactic acidosis such as feeling cold or uncomfortable, severe nausea or vomiting, stomach ache, unexplained weight loss, muscular cramps, or rapid breathing.
Otiđite u bolnicu ako imate simptome laktacidoze kao što su osjećaj hladnoće i neugode, jaka mučnina ili povraćanje, bol u trbuhu, neobjašnjiv gubitak tjelesne težine, grčevi u mišićima ili ubrzano disanje.
GO-FORWARD
Informacije za liječnika
Goitre, hypothyroidism
guša, hipotireoza
golden
zlatni
golden brown pigment patches, mostly in the face; excessive hair growth
zlatnosmeđe pigmentne mrlje, ponajviše na licu; prekomjerni rast dlaka
Golimumab has been designed to attach to and block a chemical messenger in the body called tumour necrosis factor alpha (TNF-).
Golimumab je osmišljen kako bi inhibirao i vezivao se na kemijski glasnik u tijelu zvan faktor nekroze tumora alfa (TNF-).
Gonadotrophin therapy requires a certain time commitment by physicians and supportive health professionals, as well as the availability of appropriate monitoring facilities.
Terapija gonadotropinom zahtijeva određenu vremensku obvezu liječnika i pomoćnih zdravstvenih djelatnika te postojanje odgovarajuće opreme i mogućnosti praćenja postupka liječenja neplodnosti.
Gonadotropin releasing factor (GnRF) analogue-protein conjugate min.
Konjugat analog-proteina gonadoliberina (GnRF) min.
GONAL f is presented as a powder and solvent for injection.
GONAL-f je u dostupan obliku praška i otapala za injekciju.
GONAL-f 1050 IU/1.75 mL (77 micrograms/1.75 mL) powder and solvent for solution for injection.
GONAL-f 1050 IU/1,75 ml (77 mikrograma/1,75 ml) prašak i otapalo za otopinu za injekciju.
GONAL-f 1050 IU/1.75 ML (77 MICROGRAMS/1.75 ML), VIAL LABEL
GONAL-f 1050 IU/1,75 ml (77 MIKROGRAMA/1,75 ML), NALJEPNICA BOČICE
GONAL-f 300 IU/0.5 mL
GONAL-f 300 IU/0,5 ml
GONAL-f 300 IU/0.5 ML (22 MICROGRAMS/0.5 ML) PEN, PEN LABEL
GONAL-f 300 IU/0,5 ML (22 MIKROGRAMA/0,5 ML) BRIZGALICA, NALJEPNICA BRIZGALICE
GONAL-f 300 IU/0.5 mL (22 micrograms/0.5 mL) solution for injection in pre-filled pen.
GONAL-f 300 IU/0,5 ml (22 mikrograma/0,5 ml) otopina za injekciju u napunjenoj brizgalici.
GONAL-f 300 IU/0.50 mL (22 micrograms/0.50 mL) powder and solvent for solution for injection.
GONAL-f 300 IU/0,50 ml (22 mikrograma/0,50 ml) prašak i otapalo za otopinu za injekciju.
GONAL-f 300 IU/0.50 ML(22 MICROGRAMS/0.50 ML), VIAL LABEL
GONAL-f 300 IU/0,50 ML (22 MIKROGRAMA/0,50 ML), NALJEPNICA BOČICE
GONAL-f 450 IU/0.75 ML (33 MICROGRAMS/0.75 ML) PEN, PEN LABEL
GONAL-f 450 IU/0,75 ML (33 MIKROGRAMA/0,75 ML) BRIZGALICA, NALJEPNICA BRIZGALICE
GONAL-f 450 IU/0.75 mL (33 micrograms/0.75 mL) powder and solvent for solution for injection.
GONAL-f 450 IU/0,75 ml (33 mikrograma/0,75 ml) prašak i otapalo za otopinu za injekciju.
GONAL-f 450 IU/0.75 mL (33 micrograms/0.75 mL) solution for injection in pre-filled pen.
GONAL-f 450 IU/0,75 ml (33 mikrograma/0,75 ml) otopina za injekciju u napunjenoj brizgalici.
GONAL-f 450 IU/0.75 ML (33 MICROGRAMS/0.75 ML), VIAL LABEL
GONAL-f 450 IU/0,75 ml (33 MIKROGRAMA/0,75 ML), NALJEPNICA BOČICE
GONAL-f 75 IU (5.5 micrograms) powder and solvent for solution for injection.
GONAL-f 75 IU (5,5 mikrograma) prašak i otapalo za otopinu za injekciju.
GONAL-f 75 IU (5.5 MICROGRAMS) VIAL LABEL
NALJEPNICA NA BOČICI ZA GONAL-F 75 IU (5,5 MIKROGRAMA)
GONAL-f 75 IU (5.5 μg) powder for solution for injection Follitropin alfa
GONAL-f 75 IU (5,5 μg) prašak za otopinu za injekciju folitropin alfa s.c.
GONAL-f 900 IU/1.5 ML (66 MICROGRAMS/1.5 ML) PEN, PEN LABEL
GONAL-f 900 IU/1,5 ML (66 MIKROGRAMA/1,5 ML) BRIZGALICA, NALJEPNICA BRIZGALICE
GONAL-f 900 IU/1.5 mL (66 micrograms/1.5 mL) solution for injection in pre-filled pen.
GONAL-f 900 IU/1,5 ml (66 mikrograma/1,5 ml) otopina za injekciju u napunjenoj brizgalici.
GONAL-f dose may be increased, depending on your response.
Doza lijeka GONAL-f može se povećati, što ovisi o Vašem odgovoru.
GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency.
GONAL-f se u kombinaciji s pripravkom luteinizirajućeg hormona (LH) preporučuje za stimulaciju razvoja folikula u žena s teškim nedostatkom LH i FSH.
GONAL-f is expected to have no or negligible influence on the ability to drive and use machines.
GONAL-f ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
GONAL-f is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotropin (hCG) therapy.
GONAL-f je indiciran u stimulaciji spermatogeneze u muškaraca s kongenitalnim ili stečenim hipogonadotropnim hipogonadizmom uz istovremenu terapiju humanim korionskim gonadotropinom (hCG).
GONAL-f is intended to be given by injection just under the skin (subcutaneously).
GONAL-f je namijenjen za potkožnu primjenu injekcijom (supkutano).
GONAL-f is intended to be given by injection just under the skin (subcutaneously).
GONAL-f je namijenjen za potkožnu primjenu injekcijom.
GONAL-f is presented as a clear, colourless liquid for injection in a pre-filled pen.
GONAL-f se isporučuje kao bistra, bezbojna tekućina za injekciju u napunjenoj brizgalici.
GONAL-f is presented as a powder and solvent for solution which are used to prepare a solution for injection.
GONAL-f se isporučuje kao prašak i otapalo za otopinu se koriste za pripremu otopine za injekciju.
GONAL-f is presented as a powder and solvent which are used to prepare a solution for injection.
GONAL-f se isporučuje kao prašak i otapalo koji se koriste za pripremu otopine za injekciju.
GONAL-f is presented as a powder and solvent which are used to prepare a solution for injection.
GONAL-f se isporučuje kao prašak i otapalo se koriste za pripremu otopine za injekciju.
GONAL-f is supplied in packs of 1 vial of powder with 1 pre-filled syringe of solvent and 15 disposable syringes for administration graduated in International Units (IU FSH).
GONAL-f je dostupan u pakiranju od 1 bočice s praškom s 1 napunjenom štrcaljkom s otapalom i 15 štrcaljki za jednokratnu uporabu za primjenu lijeka graduiranih u internacionalnim jedinicama (IU FSH).
GONAL-f is supplied in packs of 1 vial of powder with 1 pre-filled syringe of solvent and 4 disposable syringes for administration graduated in International Units (IU FSH).
GONAL-f je dostupan u pakiranju od 1 bočice s praškom s 1 napunjenom štrcaljkom s otapalom i 4 štrcaljke za jednokratnu uporabu za primjenu lijeka graduiranih u internacionalnim jedinicama (IU FSH)
GONAL-f is supplied in packs of 1 vial of powder with 1 pre-filled syringe of solvent and 6 disposable syringes for administration graduated in International Units (IU FSH).
GONAL-f je dostupan u pakiranju od 1 bočice s praškom s 1 napunjenom štrcaljkom s otapalom i 6 štrcaljki za jednokratnu uporabu za primjenu lijeka graduiranih u internacionalnim jedinicama (IU FSH).
GONAL-f is supplied in packs of 1 vial of powder with 1 vial of solvent.
GONAL-f je dostupan u pakiranju od 1 bočice s praškom s 1 bočicom otapala.
GONAL-f is supplied in packs of 1, 5, 10 vials of powder with the corresponding number of solvent in pre-filled syringes.
GONAL-f je dostupan u pakiranjima od 1, 5 i 10 bočica praška s odgovarajućim brojem otapala u napunjenim štrcaljkama.
GONAL-f is usually given every day.
GONAL-f obično se daje svaki dan.
GONAL-f may be given as a course of daily injections.
GONAL-f se može davati u obliku dnevnih injekcija.
GONAL-f must be reconstituted with the solvent before use (see section “How to prepare and use the GONAL-f powder and solvent” in the package leaflet).
GONAL-f mora se rekonstituirati s otapalom prije upotrebe (u Uputi o lijeku vidjeti dio „Kako se priprema i primjenjuje prašak i otapalo lijeka GONAL f “).
GONAL-f should be given at a dose of 150 IU three times a week, concomitantly with hCG, for a minimum of 4 months.
GONAL-f treba primjenjivati u dozi od 150 IU tri puta tjedno, paralelno s hCG-om, kroz najmanje 4 mjeseca.
Good blood management practices should always be used in the perisurgical setting.
U kiruškom okruženju treba uvijek primijeniti dobru praksu postupanja s krvi.
Good injection sites are the top of the thigh and around the tummy (abdomen) but away from the navel.
Pogodna mjesta za injiciranje su gornji dio bedra, područje oko trbuha (abdomena), ali dalje od pupka.
Good management and hygiene practices should be followed to reduce the risk of re-infection.
Da bi se smanjio rizik od ponovne infekcije treba uvesti mjere dobrog gospodarenja i higijene.
Good management and hygiene practices should be introduced in order to reduce the risk of re- infection.
Da bi se smanjio rizik od ponovne infekcije treba uvesti mjere dobrog gospodarenja i higijene.
Good management and hygiene practices should be introduced to reduce the risk of re-infection.
Da bi se smanjio rizik od ponovne infekcije treba uvesti mjere dobrog gospodarenja i higijene.
Good places for the injection are the upper thigh or around the belly (abdomen) at least 5 cm away from the navel (belly button)
Dobra mjesta za davanje injekcije su gornji dio bedara ili na trbuhu (abdomen), najmanje 5 cm od pupka.
Good sites are the top of the thigh and around the tummy (abdomen) but away from the navel.
Prikladna mjesta su gornji dio bedara, trbuh (abdomen) osim područja oko pupka.
Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures, such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting.
Dobra veterinarska praksa preporučuje da se antiemetici koriste uz potporu drugih mjera kao što su dijetna prehrana i nadoknada izgubljenih tekućina.
Goose Parvovirus
Guščiji parvovirus
gout (a condition of painful, swollen joints caused by uric acid crystals) worsening of food allergies.
giht (stanje bolnih, nateknutih zglobova uzrokovanih kristalima mokraćne kiseline) pogoršanje alergije na hranu.
gout abnormal blood tests (decreased glucose, elevated potassium, abnormal liver function, elevated type of white blood cell i.e. eosinophilia)
poremećeni krvni nalazi (snižena glukoza, povišen kalij, poremećena funkcija jetre, povišena jedna vrsta bijelih krvnih stanica, tj. eozinofilija)
Gout flares
Pogoršanje gihta
Gout flares may occur during initiation of treatment due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits (see section 4.8 and 5.1).
Na početku liječenja mogu nastupiti akutni napadi gihta, zbog promjena razine mokraćne kiseline u serumu koja dovodi do mobilizacije urata nataloženih u tkivima (vidjeti dijelove 4.8 i 5.1).
gout medicines (allopurinol)
lijekove za giht (alopurinol)
gout medicines (allopurinol),
lijekove za giht (alopurinol),
gout medicines (allopurinol),
lijekove za liječenje gihta (alopurinol),
gout, anorexia, decreased appetite, decreased weight, increased weight, hyperglycaemia, insulin resistance, decreased high density lipoprotein, increased appetite, polydipsia, increased blood lactate dehydrogenase
giht, anoreksija, smanjen apetit, smanjena tjelesna težina, povećana tjelesna težina, hiperglikemija, rezistencija na inzulin, sniženi lipoproteini visoke gustoće, povećan apetit, polidipsija, povišena laktat dehidrogenaza u krvi
Gout.
giht.
Gout/Gouty Arthritis
Giht/Urični artritis
Gout: The recommended dose in patients with mild hepatic impairment is 80 mg.
Giht: preporučeno doziranje kod bolesnika s blagim oštećenjem funkcije jetre je 80 mg.
Gouty arthritis is caused by the deposition of a chemical called urate crystals in the body.
Urični artritis je uzrokovan nakupljanjem spoja pod nazivom kristali urata u tijelu.
GP IIb/IIIa inhibitor (N=2,882)
GP IIb/IIIa inhibitor (N=2882)
GP IIb/IIIa inhibitor (N=3,008)
inhibitor GP IIb/IIIa (N=3008)
gp inhibition.
/P-gp.
GPIIb/IIIa inhibitors were permitted for bailout use only and were used in 2.9% of patients.
Inhibitori GPIIb/IIIa bili su dopušteni samo za primjenu u nuždi (tzv."bailout" primjenu) i korišteni su u 2,9% bolesnika.
Gr.
St.
Grab pre-filled syringe safety guard to remove pre-filled syringe from tray.
Uhvatite napunjenu štcaljku za sigurnosni štitnik kako biste je izvadili iz podloge.
Grab the loose edge at either corner and peel off the second piece of the liner.
Uhvatite slobodni rub za bilo koji ugao i svucite drugi dio zaštitnog sloja.
grade
kriterijima
Grade (CTC-AE) (a)
Stupanj (CTC-AE) (a)
Grade (CTC-AE)*
Stupanj (CTC-AE)
Grade 1 and Grade 2 diabetes mellitus and Grade 4 diabetic ketoacidosis were each reported in 0.2% (1/448) of patients.
Dijabetes 1. stupnja, dijabetes 2. stupnja i dijabetička ketoacidoza 4. stupnja prijavljeni su svaki u 0,2% (1/448) bolesnika.
Grade 1 hand- foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient’s normal activities.
Sindrom šaka-stopalo 1. stupnja definiran je utrnulošću, dizestezijom/ parestezijama, trncima, bezbolnim otokom ili eritemom šaka i/ili stopala i/ili nelagodom koja ne ometa bolesnika u svakodnevnim aktivnostima.
Grade 1 hand-foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient’s normal activities.
Sindrom šaka-stopalo 1. stupnja definiran je utrnulošću, disestezijom/parestezijama, trncima, bezbolnim otokom ili eritemom šaka i/ili stopala i/ili nelagodom koja ne ometa bolesnika u svakodnevnim aktivnostima.
Grade 1 hand-foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient’s normal activities.
Sindrom šaka-stopalo 1. stupnja definiran je utrnulošću, dizestezijom/ parestezijom, žmarcima, bezbolnim otokom ili eritemom šaka i/ili stopala i/ili nelagodom koja ne ometa bolesnika u svakodnevnim aktivnostima.
Grade 1 hand-foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient’s normal activities.
Sindrom šaka-stopalo 1. stupnja definiran je utrnulošću, dizestezijom/parestezijom, trncima, bezbolnim otokom ili eritemom šaka i/ili stopala i/ili nelagodom koja ne ometa bolesnika u svakodnevnim aktivnostima.
Grade 1 or Grade 2 (tolerable)
Stupanj 1 ili Stupanj 2 (podnošljivo)
Grade 1 RPED
RPED 1. stupnja
Grade 1-2
1. – 2. stupanj
Grade 1-2 (mild to moderate): Once the patient’s condition is stable, the infusion should be resumed at no more than half the rate at which the IRR occurred.
Reakcija 1. ili 2. stupnja (blaga do umjerena): Nakon što je stanje bolesnika stabilno, infuziju treba nastaviti brzinom koja je najmanje upola manja od one pri kojoj je nastupila reakcija na infuziju.